louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02801214: Emotional Brain Processes in Recreational Cannabis Users
Official title: Effects of Recreational Cannabis Use on Brain Activation Patterns Associated With Emotional Processes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Recreational Cannabis Use
Keywords: cannabis
fMRI
emotion
Lead sponsor: University of Electronic Science and Technology of China
Sponsor class: OTHER
Collaborators: name: German Research Foundation
name: University Hospital, Bonn
First posted: 2016-06-15
Enrollment: 50
Sex: MALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Recreational male cannabis users

Brief summary: This fMRI study investigates neural correlates of emotion regulation, emotion processing and craving in recreational cannabis users.


Eligibility criteria: Inclusion Criteria:

* Recreational cannabis use
* 72 hours of abstinence

Exclusion Criteria:

* neurological disorders
* psychiatric disorders according to DSM-4

Primary outcomes:
measure: fMRI neural correlates of emotional brain processes in recreational cannabis users after 72 hours of abstinence
timeFrame: one time point = fMRI assessment after 72 hours of abstinence
Secondary outcomes:
measure: Ratings of subjective experience (affect, craving)
timeFrame: one time point = during fMRI assessment after 72 hours of abstinence
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00448214: Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
Official title: Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation - A Double Blind, Parallel, Dose-finding Study in Comparison With Open Label Warfarin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Atrial Fibrillation
Keywords: Factor Xa inhibitor
Atrial fibrillation
Stroke
Ischemic attack
thromboembolism
Prevention and control
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2007-03-16
Enrollment: 448
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To evaluate the safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation (NVAF)and to obtain information on pharmacokinetics and pharmacodynamics (anti-thrombotic potential) in the target population


Eligibility criteria: Inclusion Criteria:

Subjects are eligible for the study if all of the following apply:

* Subject has paroxysmal permanent or persistent NVAF
* Subject has INR of 2.0 or below and an aPTT ≤ 1.5 times the upper limit of normal at the baseline visit.
* Legal minimum age requirement (country-specific).
* Written informed consent has been obtained.

Exclusion Criteria:

* History of heart valve disorders
* History of rheumatic fever.
* History of stroke and/or systemic embolism (including TIA).
* History of Acute Coronary Syndrome (ACS).
* Indication for warfarin other than NVAF.
* Known hemorrhagic disorder and/or coagulation disorder.
* Active bleeding or any condition associated with increased risk of bleeding.

Primary outcomes:
measure: All clinically relevant bleeds during the treatment period rated as "major" or "clinically relevant non-major(CRNM)"
timeFrame: 16 Weeks
Secondary outcomes:
measure: Incidence of symptomatic stroke
timeFrame: 16 Weeks
measure: Incidence of transient ischemic attack (TIA)
timeFrame: 16 Weeks
measure: Incidence of systemic thromboembolic event
timeFrame: 16 Weeks
measure: Incidence of the bleeding rates
timeFrame: 16 Weeks
measure: Other safety assessments
timeFrame: 16 Weeks
measure: PK, PD variables
timeFrame: 16 Weeks
Other outcomes:
Locations:
city: Launceston
country: Australia
city: Pok Fu Lam
country: Hong Kong
city: Sha Tin
country: Hong Kong
city: Hokkaido
country: Japan
city: Kansai
country: Japan
city: Kanto
country: Japan
city: Kyusyu
country: Japan
city: Shikoku
country: Japan
city: Tohoku
country: Japan
city: Seoul
country: Korea, Republic of
city: kuala Lumpur
country: Malaysia
city: Hastings
country: New Zealand
city: Singapore
country: Singapore
city: Bloemfontein
country: South Africa
city: Taipei
country: Taiwan
city: Bangkok
country: Thailand
city: Chiang Mai
country: Thailand
city: Nakhon Ratchasima
country: Thailand
Study officials:
affiliation: Astellas Pharma Inc
name: Central Contact
role: STUDY_CHAIR
References:
Clinical trial NCT02668614: Early Detection of Skin Cancer With Sensor Technology
Official title: Early Detection of Skin Cancer Using Millimetre-Wave Waveguide Reflectometers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Carcinoma, Basal Cell
Keywords: Detection
Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor class: OTHER
First posted: 2016-01-29
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Skin cancer represents a large problem in today's healthcare setting. The majority of cancer diagnoses are attributed to malignant skin diseases including its major types: basal cell carcinoma, squamous cell carcinoma and melanoma. Early diagnoses is critical given early detection of malignant lesions largely increases chances of successful treatment. The current gold standard of diagnosis is histopathological examination of biopsied skin. Biopsies are not only invasive and expensive, they have variable positive predictive value, meaning they may often be preformed unnecessarily. As such, the investigators have developed a skin scanner, which is less bulky and expensive than existing similar technologies, as a tool to evaluate skin lesions prior to determining the need for a biopsy. Their objective is to obtain information in order to validate this skin scanner in the context of its ability to accurately identify basal cell carcinoma skin lesions.


Eligibility criteria: Inclusion Criteria:

* Patient requiring skin biopsy for suspected basal cell carcinoma skin lesion
* 18 years of age or older

Exclusion Criteria:

-Poor english fluency, Pregnancy

Primary outcomes:
measure: Positive predictive value
timeFrame: Immediately pre-biopsy
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05060614: Analyses of Cerebrospinalfluid in Patients With Delirium
Official title: MOLECULAR BIOMARKERS IN DELIRIUM AND DEMENTIA
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Delirium
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2021-09-29
Enrollment: 700
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients acutely admitted with a hip fracture.

Brief summary: The current project aims to measure biomarkers in the cerebrospinalfluid (CSF) and serum samples from patients with delirium. We hope to uncover new insights into the pathophysiology of delirium and explore its link to dementia.

Detailed description: Delirium is a common and serious complication to acute illness, and is characterized by acute disturbances in attention, awareness, and cognition. Dementia is a major risk factor of delirium, and delirium increases the risk of dementia progression and development. As the conditions share both clinical and epidemiological features, some researchers suggest that also pathophysiological links are shared. Understanding delirium pathophysiology, which is poorly understood, may thus help elucidate early molecular mechanisms in dementia.

This study aims to to increase our understanding of the pathophysiology of delirium and molecular links between delirium and dementia, by exploring cerebrospinal fluid (CSF) biomarkers.

Eligibility criteria: Inclusion Criteria:

* Patients with acute hip fracture

Exclusion Criteria:

* Moribund patients.
* Lack of consent

Primary outcomes:
measure: Delirium
timeFrame: Daily during hospital stay (pre-/and postoperatively) until 5 days after surgery (or discharge)
Secondary outcomes:
measure: Dementia
timeFrame: Cognitive changes the first 48 months after inclusion
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Leiv Otto Watne
state: Other
Study officials:
affiliation: Oslo University Hospital
name: Leiv O Watne, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06738914: Twenty Years of Pancreatic Surgery in Iceland
Official title: Twenty Years of Pancreatic Surgery in Iceland: a Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pancreatectomy
Pancreatoduodenectomy
Distal Pancreatectomy (DP)
Lead sponsor: Linkoeping University
Sponsor class: OTHER_GOV
Collaborators: name: Landspitali University Hospital
First posted: 2024-12-18
Enrollment: 244
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who have undergone pancreatic resection in Iceland between 2003-2022. For the secondary outcome of duodenal cancer, patients with duodenal cancer who did not undergo resection in the same time span will also be included.

Brief summary: A retrospective analysis of patients undergoing pancreatic operations in Landspitali University Hospital, Reykjavik, Iceland, between 2003 and 2022.


Eligibility criteria: Inclusion Criteria:

* All patients who have undergone pancreatic resection in Iceland between 2003-2022.
* For the secondary outcome of duodenal cancer, patients with duodenal cancer who did not undergo resection in the same time span will also be included.

Exclusion Criteria: None.

Primary outcomes:
measure: Severe complications
timeFrame: 2003-2022
measure: Short-term mortality
timeFrame: 2003-2022
Secondary outcomes:
measure: Demographic, operative and postoperative data
timeFrame: 2003-2022
measure: Oncological data and survival among patients with pancreatic and periampullary cancer
timeFrame: 2003-2022
measure: Outcomes after pancreatic surgery among patients who underwent resection for cystic lesions
timeFrame: 2003-2022
measure: Comparison of patients who underwent minimally invasive distal pancreatectomy during the study period to those who underwent open distal resection.
timeFrame: 2003-2022
measure: Demographic and histopathological data as well as survival compared between patients with duodenal cancer who underwent resection and patients who did not.
timeFrame: 2003-2022
measure: Trends over time in the usage of pancreatic and minimally invasive surgery as well as changes in outcomes.
timeFrame: 2003-2022
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00801814: Effect of Escalating Doses of a Novel Viscous Polysaccharide on Postprandial Glycemia
Official title: Effect of Adding Escalating Doses of a Novel Highly Viscous Polysaccharide to Either a Liquid or a Solid Test Meal on Post Prandial Glycemia in Healthy Subjects: Determination of the Glycemic Reduction Index Potential (GRIP)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Blood Glucose, Postprandial
Keywords: viscous
fibre
polysaccharide
blood glucose
post prandial
Lead sponsor: Glycemic Index Laboratories, Inc
Sponsor class: INDUSTRY
Collaborators: name: InovoBiologic Inc.
name: Canadian Center for Functional Medicine
First posted: 2008-12-04
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: To determine palatability and extent to which escalating doses of a novel highly viscous polysaccharide \[NVP\] reduces postprandial glycemia when added to a liquid and a solid meal.


Eligibility criteria: Inclusion Criteria:

* healthy individuals
* 18-75 years old
* BMI less than 35 kg/m2

Exclusion Criteria:

* Medications influencing gastrointestinal function
* Pregnancy

Primary outcomes:
measure: postprandial glycemia
timeFrame: Acute study measuring postprandial glucose levels over 2 hours
Secondary outcomes:
measure: The glucose reduction index potential (GRIP). The GRIP factor is the reduction in glycemic index units per gram of fiber.
timeFrame: Data analysis
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Glycemic Index Laboratories, Inc.
state: Ontario
Study officials:
affiliation: Glycemic Index Laboratories, Inc
name: Alexandra L Jenkins, PhD, RD
role: STUDY_DIRECTOR
affiliation: Glycemic Index Laboratories, Inc
name: Thomas MS Wolever, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03834714: Noise Exposure and Near-Infrared Light
Official title: Effects of Noise Exposure and Near Infrared Light (NIL) on Auditory Health and Performance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hearing Loss, Noise-Induced
Keywords: Noise induced hearing loss
Near infrared energy
Hering test
Lead sponsor: University of Miami
Sponsor class: OTHER
Collaborators: name: Office of Naval Research (ONR)
First posted: 2019-02-08
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The primary objective of this work is to determine the effect noise has on the auditory system (both auditory health and performance) and also the degree to which the effect of pre-noise therapy such as Near Infrared (NIR) light can mitigate the effects of noise exposure.


Eligibility criteria: Inclusion Criteria:

* 18-45 years old, male or female
* Pass hearing exam with a threshold of 25 decibels (dB) hearing or less, for each ear, for all frequencies tested from 500 Hz to 8000 Hz
* Normal otoscopic exam, otoacoustic emissions (OAEs), and middle ear function as demonstrated by a normal tympanogram
* Completion of a hearing history questionnaire

Exclusion Criteria:

* Screening hearing test failure
* Pregnant females
* Adults unable to provide consent
* History of significant ear surgery

Primary outcomes:
measure: Change in auditory threshold
timeFrame: Baseline, up to 365 days
Secondary outcomes:
measure: Change in otoacoustic emissions (OAE)
timeFrame: Baseline, up to 365 days
measure: Change in central auditory performance (CAP)
timeFrame: Baseline, up to 365 days
Other outcomes:
Locations:
city: Fort Rucker
country: United States
facility: U.S. Army Aeromedical Research Laboratory
state: Alabama
city: Miami
country: United States
facility: University of Miami Miller School of Medicine
state: Florida
city: Wright-Patterson Air Force Base
country: United States
facility: Wright-Patterson Air Force Base
state: Ohio
Study officials:
affiliation: University of Miami
name: Michael E Hoffer, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03404414: Detection of Functioning Pituitary Microadenoma: PET/MRI Versus PET/CT
Official title: Detection of Functioning Pituitary Microadenoma With Inconclusive MRI Findings: PET/MRI Versus PET/CT
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Pituitary Adenoma
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2018-01-19
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Single Group Assignment
Primary purpose: DIAGNOSTIC

Brief summary: This is a prospective case-control study to compare the usefulness of 18F-FDG PET/MRI with that of 18F-FDG PET/CT in detection of functioning pituitary microadenomas.A single dose of 370 Mega-Becquerel (MBq) 18F-FDG will be injected intravenously.Visual and semiquantitative method will be used to assess the PET/MRI and PET/CT images.

Detailed description: Magnetic resonance imaging (MRI) may be insufficient to locate functioning pituitary microadenoma.This study compared the usefulness of 18F-FDG PET/MRI with that of 18F-FDG PET/CT in detection of functioning pituitary microadenomas in patients with inconclusive conventional MRI findings. Trans-sphenoidal adenomectomy was performed within 2 weeks of imaging.The PET/CT and PET/MRI findings and tracer uptake levels were correlated with the surgical findings and pathological results.

Eligibility criteria: Inclusion Criteria:

* Patients who were pathologically diagnosed with pituitary adenoma after surgery were recruited, and were able to provide basic information and sign the written informed consent form.

Exclusion Criteria:

* The exclusion criteria included claustrophobia, kidney or liver failure, and inability to fulfill the study.

Primary outcomes:
measure: Standardized uptake value of 18F-FDG in pituitary adenoma
timeFrame: 5 years
Secondary outcomes:
measure: Adverse events collection
timeFrame: 1 week
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
state: Beijing
Study officials:
affiliation: Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College
name: Zhaohui Zhu, M.D.,PhD
role: STUDY_CHAIR
References:
Clinical trial NCT03483714: Muscle Activation Characteristics During Spinal Manipulation in Healthy and Low Back Pain Participants
Official title: Muscle Activation Characteristics During Spinal Manipulation in Healthy and Low Back Pain Participants
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Back Pain
Keywords: Manipulation
Spinal
electromyography
kinetics
kinematic
Lead sponsor: University of Denver
Sponsor class: OTHER
First posted: 2018-03-30
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: community sample

Brief summary: To characterize muscle activity through electromyography (EMG) of the lumbar spine during high velocity, low amplitude (HVLA) spinal manipulation according to parameters of practitioner contact (location, applied force) in healthy participants and two categories of low back pain participants.


Eligibility criteria: Inclusion Criteria:

* male and female participants ages 18 to 55 years old

Exclusion Criteria:

Active Worker's Compensation claim related to low back pain episode Active personal injury case related to low back pain episode Currently taking muscle relaxers, steroids, or narcotics

* Body mass index \> 30 kg/m2
* Active cancer process
* Active infection
* Pregnancy
* High risk of osteoporosis assessed using the World Health Organization Fracture Risk Assessment Tool (included in submission)
* Osteogenic conditions (see screening questionnaire)
* Premature menopause
* Latex Allergies
* Lumbar spine or pelvic surgery
* Past spinal trauma producing spinal fracture

Primary outcomes:
measure: Muscle Response
timeFrame: During spinal manipulation at the time of testing
measure: Muscle Activity Onset Delay
timeFrame: During spinal manipulation at the time of testing
Secondary outcomes:
Other outcomes:
Locations:
city: Denver
country: United States
facility: University of Denver
state: Colorado
Study officials:
affiliation: University of Denver
name: Bradley S Davidson, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Currie SJ, Myers CA, Krishnamurthy A, Enebo BA, Davidson BS. Methods of Muscle Activation Onset Timing Recorded During Spinal Manipulation. J Manipulative Physiol Ther. 2016 May;39(4):279-87. doi: 10.1016/j.jmpt.2016.03.001. Epub 2016 Apr 9.
citation: Currie SJ, Myers CA, Durso C, Enebo BA, Davidson BS. The Neuromuscular Response to Spinal Manipulation in the Presence of Pain. J Manipulative Physiol Ther. 2016 May;39(4):288-93. doi: 10.1016/j.jmpt.2016.02.011. Epub 2016 Apr 6.
citation: Myers CA, Enebo BA, Davidson BS. Optimized prediction of contact force application during side-lying lumbar manipulation. J Manipulative Physiol Ther. 2012 Nov-Dec;35(9):669-77. doi: 10.1016/j.jmpt.2012.10.010.
Clinical trial NCT06302114: Upper Extremity Asymmetries in Overhead Athletes
Official title: Upper Extremity Asymmetries in Overhead Athletes: Relationship With Injury and Performance
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Extremity Asymmetries
Injury;Sports
Performance
Keywords: Asymmetry
Injury
Performance
Overhead
Lead sponsor: Pamukkale University
Sponsor class: OTHER
Collaborators: name: The Scientific and Technological Research Council of Turkey
First posted: 2024-03-08
Enrollment: 58
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Although overhead sports have different characteristics, the movements in the shoulder and upper extremity are similar. These sports may involve a combination of symmetrical, asymmetrical, bilateral and unilateral movements. In sports involving asymmetric movements, biomechanical changes are observed in that area due to the use of the dominant extremity. One of the reliable methods to reveal the stress effects caused by biomechanical stresses is to determine limb asymmetries. Considering the literature, limb asymmetries may be related to injury and performance.


Eligibility criteria: Inclusion Criteria:

* 15 years and older
* Attending regular sports training and competitions

Exclusion Criteria:

* Acute injury during tests

Primary outcomes:
measure: Medicine ball forward throw
timeFrame: From enrollment to the end of assessment for 1 day
measure: Y balanced test
timeFrame: From enrollment to the end of assessment for 1 day
measure: Range of motion of internal and external rotation
timeFrame: From enrollment to the end of assessment for 1 day
measure: Strength of Internal and External Rotator Muscles
timeFrame: From enrollment to the end of assessment for 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Pamukkale
country: Turkey
facility: Pamukkale University
state: Denizli
Study officials:
affiliation: Munzur University
name: Erhan Kızmaz
role: PRINCIPAL_INVESTIGATOR
affiliation: Pamukkale University
name: Fatma Ünver, Professor
role: STUDY_DIRECTOR
affiliation: Pamukkale University
name: Pınar Toksöz
role: STUDY_CHAIR
References: